Catalent (NYSE:CTLT) Shares Gap Up to $54.82

Catalent, Inc. (NYSE:CTLT)’s share price gapped up before the market opened on Friday . The stock had previously closed at $54.82, but opened at $56.69. Catalent shares last traded at $56.42, with a volume of 1,102,580 shares.

Wall Street Analyst Weigh In

CTLT has been the topic of several analyst reports. StockNews.com started coverage on Catalent in a report on Saturday. They set a “sell” rating on the stock. Stephens reissued an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $54.05.

Catalent Price Performance

The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The company has a market cap of $10.23 billion, a PE ratio of -9.26, a P/E/G ratio of 6.59 and a beta of 1.20. The stock has a 50-day simple moving average of $55.51 and a 200 day simple moving average of $53.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Equities analysts expect that Catalent, Inc. will post 0.28 EPS for the current year.

Insiders Place Their Bets

In other news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.31% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CTLT. Vanguard Group Inc. boosted its position in shares of Catalent by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after purchasing an additional 365,648 shares during the period. Capital World Investors boosted its position in shares of Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares during the period. Nomura Holdings Inc. boosted its position in shares of Catalent by 149.4% in the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares during the period. Cadian Capital Management LP boosted its position in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after purchasing an additional 759,600 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Catalent by 65.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.